HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland

Abstract : Background: Case reports have suggested an association between dipeptidyl peptidase-4 inhibitors (DPP4is) and development of bullous pemphigoid (BP). Objective: To evaluate the association between DPP4i treatment and development of BP. Methods: We conducted a retrospective 1:2 case-control study, comparing case patients with diabetes and BP with age- and sex-matched control patients with diabetes issued from Swiss (Bern) and French (Marseille) dermatologic departments from January 1, 2014, to July 31, 2016. Results: We collected 61 case patients with diabetes and BP and 122 controls. DPP4is were associated with an increased risk for development of BP (adjusted odds ratio, 2.64; 95% confidence interval, 1.19-5.85; P = .02), with vildagliptin showing the highest adjusted odds ratio (3.57 [95% confidence interval, 1.07-11.84; P = .04]). Stratified analysis showed a stronger association in males and patients age 80 years or older. DPP4i withdrawal and the initiation of first-line treatments led to clinical remission in 95% of cases. Limitations: This was a retrospective study in tertiary referral hospitals. We focused the analysis on DPP4i intake, without analyzing the potential isolated effect of metformin. Conclusions: DPP4is, especially vildagliptin, are associated with an increased risk for development of BP. Their use needs to be carefully evaluated, particularly in high-risk patients, such as males and those age 80 years or older.
Complete list of metadata

Cited literature [19 references]  Display  Hide  Download

https://hal-amu.archives-ouvertes.fr/hal-01757606
Contributor : Rene Valero Connect in order to contact the contributor
Submitted on : Tuesday, April 10, 2018 - 11:44:35 AM
Last modification on : Tuesday, May 3, 2022 - 11:04:03 AM

File

PIIS0190962217328785[1].pdf
Files produced by the author(s)

Identifiers

Collections

Citation

Michael Benzaquen, Luca Borradori, Philippe Berbis, Simone Cazzaniga, Rene Valero, et al.. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland. Journal of The American Academy of Dermatology, Elsevier, In press, 78 (6), pp.1090 - 1096. ⟨10.1016/j.jaad.2017.12.038⟩. ⟨hal-01757606⟩

Share

Metrics

Record views

109

Files downloads

93